-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下:QRVO公佈的3月季度營收為8.083億美元(季減19%,年減7%),非GAAP每股收益為1.69美元,分別超出預期的8.02億美元和1.01美元。非GAAP毛利率達到52.6%(季增350個基點,年增670個基點),顯著高於48.5%的預期,顯示儘管受到蘋果季節性因素和安卓系統退出市場帶來的營收不利影響,其毛利率仍實現了顯著增長。強勁的業績凸顯了策略成本優化和產品組合改進的有效性。管理層維持了2027財年非GAAP毛利率高於50%和每股收益接近7.00美元的目標,顯示對業績持續改善充滿信心。高效能類比元件公司業績穩健,營收達2.027億美元(季增6%,年增8%),營業利潤率達34.7%,主要得益於汽車和國防業務的強勁表現。公司創造了2.55億美元的自由現金流,並執行了4億美元的股票回購計劃,展現了管理層在等待完成對Skyworks Solutions Inc.(SWKS 73 ***)收購的同時,對公司前景的信心。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.